- Home
- REVB vs WLDS Comparison
REVB vs WLDS Comparison
Compare REVB & WLDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- WLDS
- Stock Information
- Founded
- REVB 2020
- WLDS 2014
- Country
- REVB United States
- WLDS Israel
- Employees
- REVB N/A
- WLDS N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- WLDS Computer Communications Equipment
- Sector
- REVB Health Care
- WLDS Telecommunications
- Exchange
- REVB Nasdaq
- WLDS Nasdaq
- Market Cap
- REVB 2.2M
- WLDS 2.0M
- IPO Year
- REVB N/A
- WLDS 2022
- Fundamental
- Price
- REVB $0.86
- WLDS $1.62
- Analyst Decision
- REVB
- WLDS
- Analyst Count
- REVB 0
- WLDS 0
- Target Price
- REVB N/A
- WLDS N/A
- AVG Volume (30 Days)
- REVB 2.8M
- WLDS 988.6K
- Earning Date
- REVB 05-08-2025
- WLDS 12-24-2024
- Dividend Yield
- REVB N/A
- WLDS N/A
- EPS Growth
- REVB N/A
- WLDS N/A
- EPS
- REVB N/A
- WLDS N/A
- Revenue
- REVB N/A
- WLDS $522,000.00
- Revenue This Year
- REVB N/A
- WLDS N/A
- Revenue Next Year
- REVB N/A
- WLDS N/A
- P/E Ratio
- REVB N/A
- WLDS N/A
- Revenue Growth
- REVB N/A
- WLDS 536.59
- 52 Week Low
- REVB $0.77
- WLDS $1.20
- 52 Week High
- REVB $60.80
- WLDS $54.40
- Technical
- Relative Strength Index (RSI)
- REVB 20.22
- WLDS 47.28
- Support Level
- REVB $0.78
- WLDS $1.60
- Resistance Level
- REVB $1.15
- WLDS $1.74
- Average True Range (ATR)
- REVB 0.23
- WLDS 0.15
- MACD
- REVB -0.15
- WLDS 0.02
- Stochastic Oscillator
- REVB 3.38
- WLDS 31.11
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About WLDS Wearable Devices Ltd.
Wearable Devices Ltd develops and sells human-machine interface solutions for the smart wearables industry. These digital devices include consumer electronics, smart watches, smartphones, AR glasses, VR headsets, televisions, PCs, laptop computers, drones, robots, etc. The company has completed the transition phase from research and development to commercialization of technology into B2B and B2C products. Its products include Mudra Inspire, a band for the Apple Watch that allows touchless operation and control of Apple ecosystem devices such as iPhone, Mac computer, Apple TV, and iPad, inter alia.